Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

doi:10.1158/1078-0432.CCR-15-1762

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2016

Krepler Clemens, Xiao Min, Sproesser Katrin, Brafford Patricia A, Shannan Batool, Beqiri Marilda, Liu Qin, Xu Wei, Garman Bradley, Nathanson Katherine L, Xu Xiaowei, Karakousis Giorgos C, Mills Gordon B, Lu Yiling, Ahmed Tamer A, Poulikakos Poulikos I, Caponigro Giordano, Boehm Markus, Peters Malte, Schuchter Lynn M, Weeraratna Ashani T, Herlyn Meenhard

Abstract excerpt

PURPOSE: To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models. EXPERIMENTAL DESIGN: We established 12 PDXs from BRAF inhibitor-progressed melanoma patients. Following expansion, PDXs were analyzed using targeted sequencing and reverse-phase protein arrays. By using multi-arm preclinical trial designs, we identified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Mitogen-Activated Protein Kinases

Share to Molecular Targeted Therapy

Share to Phosphatidylinositol 3-Kinases

Share to Proteomics

Share to Proto-Oncogene Proteins c-met

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26673799
DOI: 10.1158/1078-0432.CCR-15-1762
PMCID: PMC4818716

Genes

BRAF
MET
NRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.PMID 26673799Read ↗

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Semantic proximity Read ↗

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.Semantic proximity Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.Semantic proximity Read ↗

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentSemantic proximity Read ↗

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.Semantic proximity Read ↗

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapySemantic proximity Read ↗

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed MelanomasSemantic proximity Read ↗

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.Semantic proximity Read ↗

Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures.Semantic proximity Read ↗

Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation.Semantic proximity Read ↗

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.